Risk Strategies Consulting: Q4 2023 Clinical Rx Pipeline Report

Risk Strategies Consulting’s fourth-quarter Clinical Rx Pipeline Report is now available. This edition provides updates on impactful drug approvals and a forward-looking analysis of the clinical biosimilar and cell & gene therapy pipelines. In addition, the report reviews multiple topics including:

• Approval of Zepbound (tirzepatide) for chronic weight management
• Recent subcutaneous dosing formulation approvals that could result in a shift in spend from medical to pharmacy
• A new psoriasis biologic demonstrating super efficacy to existing therapies
• Approvals and upcoming launches for first-time biosimilars in 2024

As a full-service consultancy with on-staff clinicians and pharmacists for plan sponsors with mid-to-high aggregate drug spend, this knowledge is critical for managing costs and strategic planning. Our team of clinical experts is here to help.